Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report.
- PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report.
- Our investment in corporate responsibility encompasses our philanthropic endeavors, mission-focused and inclusive culture, environmental stewardship, and strong business ethics and integrity.
- In February 2024, Amicus was certified as a Great Place to Work in the United States, United Kingdom, Italy, Germany, Spain, France, and Japan.
- To access the full 2024 ESG Report, please visit www.amicusrx.com/responsibility/environmental-social-governance/ .